Literature DB >> 1968681

Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin.

I L Andrulis1, R Argonza, A E Cairney.   

Abstract

Human cell lines resistant to L-asparaginase or albizziin were isolated by multistep selection of HT1080 fibrosarcoma and MIA PaCa-2 pancreatic carcinoma cells. Mutants were cross-resistant to both drugs, but more resistant to the drug used for selection. The drug-resistant cell lines expressed elevated levels of asparagine synthetase activity and protein, up to 17-fold over that of the parental cells. Enzyme overproduction was due to gene amplification in the albizziin-resistant cells, whereas increased expression without amplification was observed in L-asparaginase-resistant cells.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1968681     DOI： 10.1007/bf01650480

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN： 0740-7750


  7 in total

Review 1.  Asparagine synthetase chemotherapy.

Authors:  Nigel G J Richards; Michael S Kilberg
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

Review 2.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

3.  Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage.

Authors:  T G Paulson; A Almasan; L L Brody; G M Wahl
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells.

Authors:  A M Aslanian; B S Fletcher; M S Kilberg
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

5.  Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.

Authors:  J C Panetta; A Gajjar; N Hijiya; L J Hak; C Cheng; W Liu; C H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2009-09-09       Impact factor: 6.875

6.  Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.

Authors:  Wei-Wen Chien; Céline Le Beux; Nicolas Rachinel; Michel Julien; Claire-Emmanuelle Lacroix; Soraya Allas; Pierre Sahakian; Aurélie Cornut-Thibaut; Loïc Lionnard; Jérôme Kucharczak; Abdel Aouacheria; Thierry Abribat; Gilles Salles
Journal:  Sci Rep       Date:  2015-01-28       Impact factor: 4.379

Review 7.  Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.

Authors:  Augusto F Andrade; Kleiton S Borges; Vanessa S Silveira
Journal:  Clin Med Insights Oncol       Date:  2014-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.